Literature DB >> 7661071

Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients.

E Arbustini1, G Merlini, A Gavazzi, M Grasso, M Diegoli, R Fasani, V Bellotti, G Marinone, P Morbini, B Dal Bello.   

Abstract

The objective of this study was to investigate the spectrum of morphologic features in myocardial biopsy specimens from patients with cardiac immunocyte-derived (AL) amyloidosis. Cardiac involvement is the most important predictor of survival in AL amyloidosis. Myocardial biopsy remains the method of choice for diagnosing cardiac amyloidosis when noninvasive studies give equivocal results. Histologic, immunohistochemical, ultrastructural, and morphometric studies were made on myocardial biopsy specimens from 11 patients in whom the diagnosis of AL amyloidosis was based on the demonstration of a monoclonal immunoglobulinopathy and of amyloid deposits in tissues. Histopathologic study showed amyloid in 10 of the 11 biopsies. In one biopsy (Congo red negative), the diagnosis was made by ultrastructural identification of amyloid fibrils. In all patients, the deposits formed perimyocytic layers that measured up to 18 microns in thickness. These layers formed along the basement membranes, which were partially preserved in 5 patients and unrecognizable in 6. Interstitial nodular deposits were also present in 5 patients. Immunohistochemical studies for the characterization of the proteins in the amyloid deposits were diagnostic in 1 patient and confirmatory in 10. Nodular deposits, thick perimyocytic layers of amyloid and small myocyte diameters were associated with shorter survival of the patients. Small-vessel involvement and myofilament loss occurred in all patients. In conclusion, myocardial biopsy serves to (1) establish the diagnosis of cardiac amyloidosis; (2) characterize immunohistochemically the proteins in the amyloid fibrils and (3) assess the degree of myocyte damage and atrophy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7661071     DOI: 10.1016/0002-8703(95)90362-3

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

1.  Diagnostic endomyocardial biopsy--still useful after all these years.

Authors:  John P Veinot
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

Review 2.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

3.  Stiff heart syndrome.

Authors:  Satya S Bhupathi; Sreelatha Chalasani; Roxann Rokey
Journal:  Clin Med Res       Date:  2010-09-17

Review 4.  Amyloid in the cardiovascular system: a review.

Authors:  I Kholová; H W M Niessen
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

5.  Cardiac amyloidosis masquerading as biventricular hypertrophy in a patient with multiple myeloma.

Authors:  Haseeb Ilias Basha; Ethiraj Raj; Ghassan Bachuwa
Journal:  BMJ Case Rep       Date:  2013-07-29

6.  Prevalence of isolated atrial amyloidosis in young patients affected by congestive heart failure.

Authors:  Lia Millucci; Lorenzo Ghezzi; Giulia Bernardini; Daniela Braconi; Piero Tanganelli; Annalisa Santucci
Journal:  ScientificWorldJournal       Date:  2012-03-12

7.  The Use of Cardiac Resynchronization Therapy in Cancer Patients with Heart Failure.

Authors:  Anecita P Fadol; Elie Mouhayar; Cielito C Reyes-Gibby
Journal:  J Clin Exp Res Cardiol       Date:  2017-04-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.